• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Stressed Out: Free Cash Flow Is All That Counts Now for Valeant

With a $31 billion debt load, the drugmaker has to show it has the firepower needed to fend off creditors.
By JAMES PASSERI Oct 14, 2016 | 02:15 PM EDT
Stocks quotes in this article: VRX, PRGO

The buzz surrounding Valeant Pharmaceuticals' (VRX) upcoming earnings rollout can be both distracting and misleading.

Which drug businesses are they planning to put on the auction block? Will "crown jewel" Bausch & Lomb ever go up for sale? Will we see a recovery in Valeant's crucial dermatology businesses? Will a Hillary Clinton election win translate into a Big Pharma crackdown?

But there's only one metric that really counts, right now: free cash flow.

With nearly $31 billion in debt on the books, the beleauguered Canadian drugmaker needs to start churning out cash to fend off creditors as maturities loom. Lenders already have proven they're running the show at Valeant, after the drugmaker failed to file its annual 10-K on time with the Securities and Exchange Commission amid investigations into bookkeeping misconduct tied to Valeant's former relationship with mail-order pharmacy Philidor.

So as analysts and investors speculate on which assets CEO Joseph Papa offer up to shore up cash, let's not forget the impetus driving Valeant to sell businesses in the first place: After years of debt-fueled acquisitions, the drugmaker is up against the wall with lenders and bondholders. (Papa, formerly the head of Irish drugmaker Perrigo  (PRGO) , was named to the helm of Valeant in April, in the weeks surrounding the testimony of Valeant's former CEO Michael Pearson before a Senate subcommittee, in which he apologized for price hikes on acquired drugs and putting shareholders ahead of patients.)

Shares of Valeant, which are down more than 91% since last summer's peaks, fell more than 50% in March when Valeant announced it could be in technical default with creditors for delaying its 10-K filing, a delay that led to restrictive concessions -- including fees, restrictions on future acquisitions and on how Valeant spends its free cash.

To quote Valeant's 10-K, which was finally filed in late April, violating debt covenants again could lead to more stringent concessions, meaning the company could be "forced into bankruptcy or liquidation and, as a result, investors could lose all or a portion of their investment in our securities."

Valeant added that a "failure to comply with these covenants could trigger events, which, if not cured or waived, could result in the acceleration of the related debt, a cross-default or cross-acceleration to other debt, foreclosure upon any collateral securing the debt and termination of any commitments to lend, each of which would have a material adverse effect on our business, [and] financial condition."

That is why price targets on Valeant's stock vary so widely, even within individual investment firms. RBC Capital Markets, for instance, said in a Wednesday investment note that Valeant's stock, which traded Friday at $22.25, has an upside potential of $71 and downside of $10, depending on whether Valeant can begin to generate meaningful organic growth. RBC also lowered its price target on Valeant Wednesday by $1, to $35, and suggested that Papa will likely lower the company's annual earnings guidance on its third-quarter earnings call. (Valeant's earnings are expected to be rolled out this month, but the date has yet to be specified.)

"We anticipate that Valeant will lower its 2016 guidance to about $9.7 billion to $9.9 billion in revenue (from $9.9 billion to $10.1 billion), $4.5 billion to $4.7 billion in adjusted EBITDA (from $4.8 billion to $4.95 billion),
and $6.25 to $6.55 in adjusted earnings per share," which is down from prior guidance of $6.60 to $7, RBC Capital analyst Douglas Miehm said.

Overall, the average consensus estimate is that Valeant's earnings will clock in at $1.77 a share, which is down 35% year-over-year, and sales are expected to clock in at $2.5 billion, down about 10% over the period. 

Valeant is a member of Real Money's Stressed Out watch list.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare | Earnings | Stocks | Agriculture

More from Healthcare

Bearish Bets: 3 Stocks You Should Consider Shorting This Week

Bob Lang
Jul 3, 2022 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Nuvalent Has Begun the Bottoming Process

Bruce Kamich
Jul 1, 2022 10:52 AM EDT

Let's check the charts and indicators.

CRISPR Therapeutics Has Turned the Corner

Bruce Kamich
Jul 1, 2022 8:43 AM EDT

Here's our current price target.

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:34 AM EDT PAUL PRICE

    A $525,000 Vote of Confidence on Macerich (MAC)

  • 09:49 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Stop Wishing, Hoping, and Praying and Take Control...
  • 07:59 PM EDT PAUL PRICE

    Very Good Quarterly Numbers From Bassett Furniture (BSET)

    Bassett Furniture blew right through analysts es...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login